Secondary Logo

Institutional members access full text with Ovid®

Share this article on:

Towards the integration of pharmacogenetics in psychiatry

a minimum, evidence-based genetic testing panel

Bousman, Chada,b,c; Maruf, Abdullah Alc; Müller, Daniel J.d,e

Current Opinion in Psychiatry: January 2019 - Volume 32 - Issue 1 - p 7–15
doi: 10.1097/YCO.0000000000000465
MOOD AND ANXIETY DISORDERS: Edited by Sidney H. Kennedy and Hans-Ulrich Wittchen

Purpose of review The implementation of pharmacogenetic testing in psychiatry is underway but is not yet standard protocol. Barriers to pharmacogenetics becoming standard practice are the lack of translation of evidence-based recommendations and standardization of genetic testing panels. As for the latter, there are currently no regulatory standards related to the gene and allele content of testing panels used to derive medication selection and dosing advice. To address these barriers, we summarize the current gene–drug interaction knowledgebase and proposed a minimum gene and allele set for pharmacogenetic testing in psychiatry.

Recent findings The Pharmacogenomics Knowledgebase has cataloged 448 gene–drug interactions relevant to psychiatry based on the current scientific literature, drug labels, and pharmacogenetic-based implementation guidelines. A majority of these interactions involved two cytochrome P450 enzymes (CYP2D6 and CYP2C19) and antidepressant medications, however, CYP2C9, HLA-A, and HLA-B are relevant to mood stabilizers/anticonvulsants.

Summary On the basis of evidence base, we proposed a minimum gene and allele set for pharmacogenetic testing in psychiatry that includes 16 variant alleles within five genes (CYP2C9, CYP2C19, CYP2D6, HLA-A, HLA-B). The intent is to assist clinicians in judging the gene and allele content of pharmacogenetic tests and to facilitate pharmacogenetic testing as a standard protocol and companion tool for psychotropic medication selection and dosing.

aDepartments of Medical Genetics, Psychiatry, Physiology & Pharmacology, University of Calgary

bAlberta Children's Hospital Research Institute

cMathison Centre for Mental Health Research and Education, Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada

dPharmacogenetics Research Clinic, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health

eDepartment of Psychiatry, University of Toronto, Toronto, Ontario, Canada

Correspondence to Chad Bousman, Department of Medical Genetics, University of Calgary, 228 HMRB, 3330 Hospital Drive NW, Calgary, AB T2N 4N1, Canada. Tel: +1 403 441 8409; e-mail: chad.bousman@ucalagary.ca

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.